Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ogalvibart/C 144LS

Next Previous
X
Search
Drug Profile

Ogalvibart/C 144LS

Alternative Names: Anti-SARS-CoV-2 mAbs - Bristol Myers Squibb; BMS-986414+BMS-986413; BMS-986414/C 144LS; C 144LS/BMS-986414; C 144LS/IM051; C 144LS/ogalvibart; C-135-LS/C-144-LS; C-144-LS/C-135-LS; COVID-19 mAbs - Bristol Myers Squibb; IM051/C 144LS; Monoclonal antibody duo - Bristol Myers Squibb; SARS-CoV-2 neutralising monoclonal antibody combination - Bristol Myers Squibb

Latest Information Update: 11 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rockefeller University
  • Developer National Institute of Allergy and Infectious Diseases; Rockefeller University; Xencor
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections

Most Recent Events

  • 20 Jun 2023 National Institute of Allergy and Infectious Diseases (NIAID) completes phase-II/III ACTIV-2 trial in COVID-2019 infections in USA, Argentina, Brazil, Canada, South Africa, Mexico, Philippines and Puerto Rico (Inhalation) (NCT04518410)
  • 02 Aug 2022 Rockefeller University completes a phase I trial (In volunteers) in COVID-2019 infections (IV, SC) in USA (NCT04700163)
  • 10 Mar 2022 Bristol-Myers Squibb completes enrolment in its phase II trial for COVID-2019 infections (Prevention) in the US (Bristol-Myers Squibb 10-K, December 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top